![Olga Danilchanka](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Olga Danilchanka
Directeur/Membre du Conseil chez
Therini Bio, Inc.
Profil
Olga Danilchanka is currently Director at Therini Bio, Inc. since 2021.
Dr. Danilchanka is also Partner at Merck Research Ventures since 2018, with the title of Partner starting in 2024.
Dr. Danilchanka earned a doctorate from The University of Alabama at Birmingham in 2010.
Postes actifs de Olga Danilchanka
| Sociétés | Poste | Début |
|---|---|---|
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Private Equity Investor | 01/05/2021 |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Directeur/Membre du Conseil | 01/11/2021 |
Formation de Olga Danilchanka
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
41
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The University of Alabama at Birmingham
 The University of Alabama at Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Finance |
Therini Bio, Inc.
Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Commercial Services |
